Traders should monitor the upcoming Q2 2026 clinical data readouts for MT-601 in lymphoma and the initiation of the pancreatic cancer trial, which could serve as near-term catalysts. However, declining grant revenue and persistent losses raise funding risk beyond 2026 without dilution or new grants.
Price Chart
Executive Summary
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.
Key Financial Metrics
Key Facts
- Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
- Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
- Cash runway expected through Q4 2026 without additional grant funding.
- MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.
- Nature Medicine publication reported up to 84.6% disease control rate in pancreatic cancer with MT-601 combination therapy.
- Company-sponsored pancreatic cancer trial expected to initiate in Q2 2026.
- Grant income declined sharply to $3.5M in 2025 from $6.6M in 2024.
Financial Impact
Revenue declined 46% YoY to $3.5M due to lower grant income; net loss increased 13% despite cost reductions; cash burn was $12.0M in 2025.
Risk Factors
- Limited cash runway extending only to Q4 2026 with no guarantee of additional grant disbursements.
- Heavy reliance on non-dilutive funding; decline in grant income raises sustainability concerns.
- Clinical-stage biotech risk: value hinges on unproven therapies with no near-term revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258655 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Mar 20, 2026 27w ago | DEFA14A | $1.31 $1.35 | ▲ +3.05% | ▼ −10.00% | $1.05 (−19.85%) |
Mar 19, 2026 28w ago | 8-K | $1.32 $1.38 | ▲ +4.55% | ▼ −9.80% | $1.05 (−20.45%) |
Mar 18, 2026 28w ago | Press Release | $1.32 $1.38 | ▲ +4.55% | ▼ −9.80% | $1.05 (−20.45%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access